AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02359513
Drug: Antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bulimic patients are treated during 3 months
Trial: NCT03335280
Drug: 68Ga-citrate PET/MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
Trial: NCT02544828
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline) is administered after anesthesia induction
Trial: NCT02446795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
Trial: NCT02720822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo is given as one double-blind capsule in the morning.
Trial: NCT02720822
Drug: Plus laxative (Docusate with senna)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
Trial: NCT02720822
Drug: Plus placebo laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the patients are taking placebo, a placebo laxative will be offered.
Trial: NCT01818063
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01818063
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02774564
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone tablets 50 mg, oral administration
Trial: NCT02774564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone matching placebo tablets
Trial: NCT02774564
Drug: Sinemet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
Trial: NCT01919398
Drug: LY2940680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01766414
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously
Trial: NCT04885426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03796598
Drug: Fecal Microbial transplant Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules of FMT
Trial: NCT03002922
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen formula Y65-158
Trial: NCT01837797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, tablets, orally
Trial: NCT00004758
Drug: pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04381936
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
Trial: NCT04381936
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
Trial: NCT00567957
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
Trial: NCT04399356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
Trial: NCT03254160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01543412
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
Trial: NCT04107428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
Trial: NCT03052816
Drug: Motrin/Percocet/Dilaudid for breakthrough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen
Trial: NCT01000025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 45 mg PO, daily
Trial: NCT01361373
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 2 weeks
Trial: NCT00612157
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03918447
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing an inert placebo
Trial: NCT00975988
Drug: TYKERB® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administrated TYKERB® tablets according to the prescribing information
Trial: NCT00885989
Drug: SLV338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 - 1000 mg IV
Trial: NCT00885989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00669903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408434
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017 0.05mg and 1.0mg tablets
Trial: NCT02259894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02110264
Drug: XR-NTX
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
Trial: NCT00128115
Drug: MK0677
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975052
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo only on Days 1 and 2 in one of four treatment periods.
Trial: NCT01083420
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 0.2% mouthwash
Trial: NCT01601717
Drug: RTI-336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
Trial: NCT01601717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo pill administered once per day for 10 days.
Trial: NCT00387036
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
Trial: NCT00767767
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Saline infusion for 2 hours.
Trial: NCT01678820
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg tablet
Trial: NCT01678820
Drug: Placebo to simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to simvastatin 40 mg tablet
Trial: NCT02059161
Drug: MK-1293
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Trial: NCT02059161
Drug: Lantus™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Trial: NCT01629680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coated tablets identical in number and appearance as the study drug
Trial: NCT02991144
Drug: Reactive Corticosteroid Taper Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301.
Trial: NCT02991144
Drug: Prophylactic Corticosteroid Taper Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects.
Trial: NCT00007475
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
Trial: NCT03311022
Drug: Acupan® 30mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00642135
Drug: Mydriasert®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
Trial: NCT00258180
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV over 1 hour on days 1-4
Trial: NCT02912468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Trial: NCT00125593
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00125593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT01953770
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
Trial: NCT01953770
Drug: Triple intrathecal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
Trial: NCT01916941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432510
Drug: C1 esterase inhibitor [human] (C1INH-nf)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02724527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo capsule
Trial: NCT02168543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01805557
Drug: R-DHAP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy
Trial: NCT00930943
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg qd twice
Trial: NCT00003471
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01031472
Drug: GSK2248761 formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
Trial: NCT01031472
Drug: GSK2248761 reference formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 100mg Gelucire reference capsule with food
Trial: NCT01031472
Drug: GSK2248761 formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
Trial: NCT01031472
Drug: GSK2248761 formulation 2 or 4
RxNorm normalized name: Inova 8-2 Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
Trial: NCT00960752
Drug: R848 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
Trial: NCT01719601
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Trial: NCT00061113
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg, QD x 16 weeks
Trial: NCT01351025
Drug: placebo for atorvastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Trial: NCT00615134
Drug: Optimized background ARV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00525603
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2/day 3-5 IV 5-30 minutes
Trial: NCT03513601
Drug: (R)-CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
Trial: NCT00280657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Trial: NCT00097708
Drug: experimental anti-anxiety drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03510624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty capsules
Trial: NCT01861522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Placebo tablets will be taken orally twice a day
Trial: NCT01789047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT01357330
Drug: SAR245408 (XL147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule and tablet Route of administration: oral
Trial: NCT01357330
Drug: MSC1936369B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT02390739
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
Trial: NCT04755023
Drug: Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
RxNorm normalized name: bis(β-chloroethyl)methylamine
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Trial: NCT01805557
Drug: BR-DHAP
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.
Trial: NCT04307173
Drug: KBL693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral
Trial: NCT04307173
Drug: KBL693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral
Trial: NCT00810589
Drug: Humalog NPL Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,4 IE per kg bodyweight
Trial: NCT03886922
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
Trial: NCT00078286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage ranging from 50 mg to 200 mg once a day
Trial: NCT00832364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT03633994
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
Trial: NCT03633994
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline bladder instillation
Trial: NCT02738580
Drug: COS with GnRH antagonists and HP-HMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
Trial: NCT00247572
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tab from 7th-11th day of the same cycle orally 3times/day
Trial: NCT01062763
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 to 50 mg once daily
Trial: NCT01062763
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: addition of placebo 1 to 2 tablets daily
Trial: NCT03629769
Drug: Proxelan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one suppository of proxelan once a day for 30 days
Trial: NCT00186901
Drug: Calcium carbonate (Tums), vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day